#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Urea cycle disorder Emphysema HER2 gene amplification Obliterative bronchiolitis Giant cell tumour of tendon sheath Squamous cell carcinoma of the oral cavity Netherton's syndrome B precursor type acute leukaemia Malignant peritoneal neoplasm Metabolic disorder Angiosarcoma recurrent Adrenogenital syndrome Amyotrophic lateral sclerosis Angiosarcoma metastatic Cold type haemolytic anaemia More trials…

    Learn about Rare Diseases

    Leiomyosarcoma metastatic – Diagnostics Primary immunodeficiency syndrome – Basic Information Angelman’s syndrome Fabry’s disease – Basic Information Combined immunodeficiency – Basic Information Haemophilia A without inhibitors – Basic Information Tuberous sclerosis complex – Diagnostics Von Willebrand’s disease Uterine leiomyosarcoma – Basic Information Uterine leiomyosarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Teprenone Xaluritamig Tolu Balsam Ads-013 Sodium Glycerophosphate Procarbazine Hydrochloride Dorzolamide Hydrochloride Dog Epithelia Cellulose, Microcrystalline Fremanezumab Fluconazole Amiloride Metolazone Follitropin Alfa Bexotegrast Imipenem Anhydrate Mometasone Setrusumab Lixudebart Hmb-001 More therapies…

    Learn about Your Condition

    Hypervolaemia Fabry's disease Rabies Traumatic pain Biliary tract operation Eye disorder Thrombocytosis Autoimmune disorder Haemoptysis Open angle glaucoma Endometrial cancer Menopause Infertility Idiopathic pulmonary fibrosis Bile duct adenocarcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopital Henri Mondor – 1 rue Gustave Eiffel

Hopital Henri Mondor – 1 rue Gustave Eiffel

51 Av Du Mal De Lattre De Tassigny, Creteil, 94000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Daunorubicin Hydrochloride
    • Cytarabine
    • Venetoclax
    Belgium Czechia France Germany Greece Hungary +4

  • A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study testing duvakitug for patients with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • Study of Methotrexate Treatment for Patients with Erosive Hand Osteoarthritis Not Responding to Standard Therapy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Osteoarthritis
    Investigated Drugs:
    • Folic Acid
    • Sodium Chloride Solution 0.9%
    • Methotrexate
    France

  • Study of bone marrow mesenchymal cells with biomaterial to treat delayed or non-healing long bone fractures using ORTHOALLO-BM-MSC and MBCP+ in adult patients

    Recruiting

    3 1 1
    Investigated Drugs:
    • ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS, FROM SELECTED DONORS
    France Germany Italy Spain

  • Study on Brain Inflammation in Schizophrenia Patients Using 18F-DPA-714

    Recruiting

    4 1 1
    Investigated Diseases:
    • Schizophrenia
    Investigated Drugs:
    • N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
    France

  • Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • TAGRAXOFUSP
    • Venetoclax
    France

  • Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Sickle cell disease
    Investigated Drugs:
    • Rilzabrutinib
    Belgium France Germany Greece Italy The Netherlands +1

  • Study on the Safety and Effects of BMS-986470 for Patients with Sickle Cell Disease

    Recruiting

    2 1
    Investigated Diseases:
    • Sickle cell disease
    Investigated Drugs:
    • BMS-986470
    France Italy

  • Study on Rituximab for Patients with Rheumatoid Arthritis: Comparing 200 mg and 1g Doses for Maintenance Treatment

    Recruiting

    3 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Sodium Chloride Ph. Eur.
    • Sodium Hydrogen Carbonate Pheur
    • Rituximab
    France
1 2 3 … 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!